Does evening primrose oil help eczema, breast pain or hot flashes?

Gamma-linolenic acid is converted in the body to dihomo-gamma-linolenic acid (DGLA), which is the precursor to series-1 prostaglandins — a class of signaling molecules with anti-inflammatory and anti-proliferative properties⁹. This pathway is distinct from the omega-3 anti-inflammatory pathway, and the two work together to keep inflammation in check.

Many people are poor converters of linoleic acid to GLA due to genetic variation, aging, high sugar intake, alcohol, or zinc and magnesium deficiency — all of which suppress delta-6-desaturase, the enzyme that makes the conversion⁶. Supplementing with evening primrose oil delivers GLA directly, making it available regardless of conversion efficiency.

Skin and the Barrier Function

People with atopic dermatitis (eczema) often show measurably low plasma GLA and DGLA levels. Clinical research shows that restoring GLA through evening primrose oil supplementation correlates with improvement in itch, redness, and overall skin severity². A randomized placebo-controlled trial found statistically significant reductions in eczema severity after 5 months of supplementation, with 96% of EPO patients showing improvement versus 32% in the placebo group³.

The mechanism appears to involve GLA's role in maintaining the skin's lipid barrier, reducing transepidermal water loss, and dampening inflammatory cytokine activity. Evidence is stronger for children and for people with confirmed low baseline GLA levels².

Women's Health Applications

Evening primrose oil is one of the most studied natural supplements for women's hormonal health concerns:

Breast pain (mastalgia): Cyclical breast pain is linked to fatty acid imbalances affecting prostaglandin signaling. A randomized pilot trial that enrolled 85 women found that worst-pain scores improved over six months with evening primrose oil (p = 0.005), vitamin E (p = 0.04) and the two combined (p = 0.05) but not with placebo (p = 0.93); in a two-sample t-test, none of the three active groups differed significantly from placebo⁵. DGLA, which rises in plasma with EPO supplementation, is converted to series-1 prostaglandins that have anti-inflammatory and anti-proliferative properties⁹.

Menopausal hot flashes: A randomized clinical trial found evening primrose oil (500 mg daily) significantly reduced hot flash severity compared to placebo, with a 42% reduction in intensity versus 32% in the placebo group (p < 0.05)⁴. Effects were modest but meaningful for women seeking non-hormonal options.

PMS: Evidence is mixed. Some trials show meaningful reductions in PMS symptom scores after 3 months; others find effects indistinguishable from placebo. The benefit may be most pronounced in women with documented low essential fatty acid status.

Dosage and Practical Use

Typical doses in clinical studies range from 500 mg to 4,000 mg per day. Most research on skin conditions uses higher doses (2–4 g/day), while women's health studies often use 500 mg–1,500 mg/day. Effects on eczema often take 4–8 weeks to become apparent. EPO is generally well tolerated — occasional mild GI discomfort is the most commonly reported side effect¹.

Look for products standardized to at least 8–10% GLA. Evening primrose oil is less stable than saturated fats and should be stored in a cool, dark place or refrigerated after opening.

See our omega-3 page for context on how omega-3 and omega-6 anti-inflammatory pathways interact.

Atopic Dermatitis

The strongest evidence for evening primrose oil lies in atopic dermatitis. Simon et al. (2014) reported, in an open pilot study of 21 patients who took 4–6 g of EPO daily for 12 weeks, that plasma GLA and DGLA levels rose significantly at 4 and 12 weeks and that the objective SCORAD (SCORing Atopic Dermatitis) score fell. In the 14 patients who followed the protocol, bigger rises in plasma GLA went with bigger SCORAD improvements (P = 0.008)². This hints that EPO acts through its GLA content, but an open study without a placebo group cannot rule out a non-specific effect.

Senapati et al. (2008) conducted a randomized, placebo-controlled trial in patients with atopic dermatitis and found that 96% of the EPO group showed improvement after 5 months, compared to 32% in the placebo group (p < 0.00001). The scoring system covered the extent, intensity, itching, and dryness of the eczema, the analysis included the first 25 patients per group who completed the 5 months, and no significant adverse effects were reported³.

A meta-analysis by Morse and Clough (2006) of 26 randomized, placebo-controlled trials of the Efamol brand of evening primrose oil in atopic eczema, including 1,207 patients, reported a beneficial effect on itch, crusting, oedema, and redness that became apparent between 4 and 8 weeks after starting treatment. The effect was smaller in people who used potent steroids more often. The authors' listed affiliation is a supplement company (Wassen International), and the analysis covered a single brand, so its results may not apply to other evening primrose oil products⁷.

The mixed findings across studies likely reflect differences in baseline GLA status among participants — those with lower baseline levels show greater responses, which may explain why meta-analyses including unselected populations show attenuated effects.

Menopausal Vasomotor Symptoms

Farzaneh et al. (2013) conducted a double-blind RCT in 56 menopausal women (ages 45–59) receiving 500 mg EPO or placebo daily for 6 weeks⁴. The EPO group showed a 42% reduction in hot flash severity and 39% reduction in frequency, compared to 32% and 32% in placebo. The difference in severity reduction reached statistical significance (p < 0.05), though frequency and duration did not separate significantly from placebo.

A larger single-blind RCT (Kazemi et al., 2021) in 170 postmenopausal women found no statistically significant reduction in hot flash frequency, severity, or duration after 8 weeks of 1,000 mg of EPO twice daily; night sweats, however, were less frequent and less severe than in the placebo group⁸. The divergent results may reflect differences in study duration, EPO dose, and participant baseline characteristics.

A 2024 systematic review and meta-analysis concluded that EPO showed no significant benefit over placebo for vasomotor symptom frequency but noted a trend toward reduced severity that warrants further adequately powered trials.

Cyclical Mastalgia

The double-blind, placebo-controlled pilot RCT by Pruthi et al. (2010) randomized 85 women with cyclical mastalgia to vitamin E (1,200 IU/day), EPO (3,000 mg/day), both, or double placebo for six months⁵. The primary outcome was change in breast pain on the modified McGill Pain Questionnaire; only 41 women completed the study. Worst-pain scores improved with EPO (p = 0.005), vitamin E (p = 0.04) and the combination (p = 0.05) but not with placebo (p = 0.93). However, a two-sample t-test found no significant decrease for any of the three active groups compared with placebo (EPO p = 0.18; vitamin E p = 0.10; combination p = 0.16), and the authors report only a trend toward reduced severity.

The 2018 review by Timoszuk et al. in Antioxidants outlines how GLA acts. EPO supplementation raises plasma levels of GLA and of its metabolite DGLA, which is either oxidized by 15-lipoxygenase to 15-HETrE or converted by cyclooxygenase to series-1 prostaglandins; these compounds have anti-inflammatory and anti-proliferative properties. 15-HETrE also blocks the conversion of arachidonic acid to leukotriene A4 by directly inhibiting 5-lipoxygenase, and GLA suppresses inflammation mediators such as IL-1β, IL-6, and TNF-α⁹.

Safety and Limitations

Evening primrose oil has an extensive safety record in clinical trials. The 2023 comprehensive review confirms no significant adverse events at typical supplemental doses and notes it is nontoxic in animal studies even at high doses¹. Rare case reports exist of EPO lowering the seizure threshold in people on phenothiazines, and it may have mild antiplatelet effects at high doses.

Overall evidence strength: moderate for atopic dermatitis (especially in GLA-deficient individuals), weak-to-moderate for women's hormonal health applications. Effect sizes in trials are generally modest, and the most consistent benefits appear in populations with confirmed fatty acid imbalances.